Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Alex Jaimes
Observed names:
A. Jaimes,
Alex Jaimes Sánchez,
Jaimes, Alex
Institutions:
Hospital Universitario Fundación Jiménez Díaz,
Universidad Autónoma de Madrid
Observed institutions:
Hospital Clínico San Carlos,
Centre for Biomedical Network Research on Rare Diseases,
Hospital Universitario Fundación Jiménez Díaz,
Instituto de Investigación Sanitaria Fundación Jiménez Díaz,
Universidad Autónoma de Madrid
ORCID:
0000-0002-0890-9484
Observed ORCID:
0000-0002-0890-9484
OpenAlex ID:
A5028088191
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world
2024
·
Edoardo Caronna
, Victor José Gallardo
, et al.
·
Journal of Neurology Neurosurgery & Psychiatry
·
83
PDF
Machine‐learning‐based approach for predicting response to anti‐calcitonin gene‐related peptide ( CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study
2022
·
Alicia Gonzalez‐Martinez
, Josué Pagán
, et al.
·
European Journal of Neurology
·
52
PDF
Case report: Wallenberg’s syndrome, a possible cause of symptomatic epicrania fugax
2017
·
Alex Jaimes
, Rafael García-Sáez
, et al.
·
Cephalalgia
·
15
Retrospective cohort study of anti-CGRP monoclonal antibody unresponsive migraine individuals treated with atogepant: The RESCUE study
2025
·
Alex Jaimes
, Jaime Rodríguez-Vico
, et al.
·
Cephalalgia
·
13
Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
2024
·
Alex Jaimes
, Andrea Gómez
, et al.
·
Headache The Journal of Head and Face Pain
·
13
PDF
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
2026
·
Edoardo Caronna
, Rut Mas-de-les-Valls
, et al.
·
Neurology
·
12
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study
2023
·
Alicia Gonzalez-Martinez
, Ancor Sanz-García
, et al.
·
Pain Medicine
·
12
PDF
The profile of refractory chronic cluster headache
2024
·
Javier A. Membrilla
, María-Luz Cuadrado
, et al.
·
Neurological Sciences
·
11
SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials
2025
·
Cristina Sanabria-Gago
, Iris Fernández Lázaro
, et al.
·
Frontiers in Neurology
·
8
PDF
Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies
2025
·
María Clara García-Castillo
, Álvaro Sierra-Mencía
, et al.
·
Journal of Neurology
·
8
PDF
Clinical predictors of therapeutic failure of occipital nerve stimulation in refractory chronic cluster headache
2024
·
Javier A Membrilla
, María-Luz Cuadrado
, et al.
·
Cephalalgia
·
8
Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study
2022
·
Alex Jaimes
, Andrea Gómez
, et al.
·
Pain Practice
·
8
Association Between Interictal Sensory Hypersensitivities and Vestibular Symptoms in Migraine: A Cross‐Sectional Study
2025
·
Alex Jaimes
, Jaime Rodríguez‐Vico
, et al.
·
Brain and Behavior
·
6
PDF
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study
2024
·
Ana Beatriz Gago‐Veiga
, Noelia Lopez‐Alcaide
, et al.
·
European Journal of Neurology
·
6
PDF
Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
2026
·
María Clara García‐Castillo
, Álvaro Sierra‐Mencía
, et al.
·
Headache The Journal of Head and Face Pain
·
4
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
2026
·
Edoardo Caronna
, Rut Mas-de-les-Valls
, et al.
·
Neurology
·
3
PDF
De novo truncating mutation in SCN1A as a cause of febrile seizures plus (FS+)
2020
·
Alex Jaimes
, Rosa Guerrero‐López
, et al.
·
Epileptic Disorders
·
3
PDF
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort
2026
·
Edoardo Caronna
, Rut Mas-de-les-Valls
, et al.
·
Cephalalgia
·
1
Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project)
2026
·
Ana Beatriz Gago-Veiga
, Ana Belen Lopez-Rodriguez
, et al.
·
Cephalalgia
·
1
Prospective cohort study of the impact of preventive migraine treatment on vestibular function and symptoms: The SPIRAL study
2025
·
Alex Jaimes
, Jaime Rodríguez-Vico
, et al.
·
Clinical Neurology and Neurosurgery
·
1
MaMi study: Perceptions of pregnancy and reproductive decision‐making in women with migraine
2026
·
Nuria González‐García
, Blanca Hidalgo Valverde
, et al.
·
Headache The Journal of Head and Face Pain
PDF
Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)
2026
·
Ana Beatriz Gago-Veiga
, Ana Belen Lopez-Rodriguez
, et al.
·
The Journal of Headache and Pain
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)
2026
·
Ana Beatriz Gago-Veiga
, Ana Belen Lopez-Rodriguez
, et al.
·
Cephalalgia
ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
2026
·
Alba Somovilla
, Iris Fernández‐Lázaro
, et al.
·
Brain and Behavior
Vestibular asymmetry and dizziness-related disability in migraine: A cross-sectional vHIT study (DELTA study)
2026
·
Alex Jaimes
, Jaime Rodríguez-Vico
, et al.
·
Cephalalgia Reports
Show more works
View as search
Works count:
29
Citation count:
268
H-index:
8
I10-index:
8
Year
Topic
Type